Global Vaccine Access

Navendu Mishra Excerpts

Thursday 13th January 2022 Westminster Hall

[Navendu Mishra (Stockport) (Lab)]

It is a pleasure to serve under your chairmanship, Mrs Murray. I thank the hon. Member for North East Fife (Wendy Chamberlain) for securing this debate at a time when the pandemic is wreaking devastation on the poorest and most vulnerable nations on earth and brutally exposing their lack of access to vaccines. I know that she is a longstanding campaigner on the issue of equitable access to vaccines for everyone. I also thank organisations such as Global Justice Now for the important research they have done to raise awareness of this issue. I am a member of the International Development Committee; it is good to see other colleagues from the Committee attend this popular debate. The Chair of the Committee, my hon. Friend the Member for Rotherham (Sarah Champion) has done a lot of good work on this issue.

One of the reasons for the pernicious spread of coronavirus, and the high global death toll, is the failure of Governments, such as ours, to support the Agreement on Trade-Related Aspects of Intellectual Property Rights waiver, proposed by the Indian and South African Governments last summer, just months before the omicron variant emerged. That was despite India and South Africa proposing, as far back as October 2020, that a waiver of intellectual property rules on covid-19 vaccines, tests and treatments would allow low and middle-income countries to manufacture life-saving tools. Despite most countries, including the United States, supporting the waiver, the UK, the EU and Switzerland all prevented progress.

Action at the time would have led to life-saving covid vaccines, medical equipment and medicines all being produced licence-free. However, more than a year after the start of the global vaccination drive, our Government are still putting hundreds of thousands of lives at risk by not supporting the waiver. The reality is, as we all know, that no one is safe until everyone has access to vaccinations and all nations are immunised.

Sadly, instead of supporting lower and middle-income countries, our Government have actively blocked them from making their own vaccines and have continued to oppose a waiver on intellectual property rights. I would therefore like to hear the Minister respond to the concerns that she and her colleagues are continuing to block solutions to the covid pandemic, given the severity of the crisis affecting both the NHS and the economy as a result of rapidly escalating levels of omicron cases. Denying lower and middle-income countries full, unfettered access to vaccines is incredibly short-sighted and will lead to a situation whereby our own population will remain at risk.

A global disease needs a united, global effort to eradicate it and reduce the risk of further mutations. An intellectual property rights waiver is therefore a vital way to achieve that, and we must follow the lead set by the Biden Administration in supporting that. The Government abolished the Department for International Development. That was extremely short-sighted and regressive, and will ultimately cost many, many lives. What happened was shameful. To put the situation into context, in a six-week period over November and December, the EU, UK and US all received more doses than African countries took stock of in the entire year. That is truly shocking.

[Apsana Begum (Poplar and Limehouse) (Lab)]

Some 700 million doses of the vaccine were delivered instead of the 2 billion that were promised through the COVAX programme by the end of the last year. Does my hon. Friend agree with me that what is inherently wrong with the COVAX programme is that it has an unequal distribution embedded in it, and for that reason ensures that facilities that are given exclusive licences are over-relied on. Facilities can also implement export bans in their countries to stop the vaccine being distributed more widely.

[Navendu Mishra]

My hon. Friend makes a very important point, and I fully agree with her.

I will finish on the point that, despite having already made billions in profit, Pfizer and Moderna continue to refuse to share the new generation of vaccine technology with the World Health Organisation’s mRNA hub in South Africa. That is a major concern, and little appears to have been done since Amnesty International urged Governments, including our own, to deliver 2 billion vaccines to low and middle-income countries before the end of 2021. The continued failure to act will fuel an unprecedented human rights crisis and lead to an untold number of deaths in those countries. We must do more, and the Government have to do a lot better.

--- Later in debate ---

[Vicky Ford]

I will answer the points that have been made on this, and if I have time, I will give way at the end. The flexibilities within the TRIPS system that were used to tackle the HIV/AIDS crisis are really important. We remain open to all initiatives that will have a demonstrable impact on vaccine production and distribution, and we continue to engage constructively in discussions at the World Trade Organisation to that end. However, we need to focus our efforts on actions that will make timely and substantive differences, such as further voluntary licensing and technology transfer agreements. That is why we support the voluntary licensing approach taken by the team at Oxford University and AstraZeneca. Their collaboration with the Serum Institute of India has massively scaled up manufacturing for global supply.

On manufacturing, we are also providing technical support to develop business cases for Biovac to manufacture vaccines in South Africa, to Institut Pasteur in Dakar, Senegal and to the Moroccan Government. This technical support is helping to catalyse the investment that will see those vaccines produced on the African continent this year. We are also engaging with the new Partnership for African Vaccine Manufacturing. Focusing on supporting manufacturing on the continent of Africa is absolutely one of my key priorities. However, vaccine supply must be matched by the capacity of health systems to deliver them. We have been working to support and strengthen health systems in some of the most vulnerable countries, and we recently launched the “Health Systems Strengthening” position paper, which sets out our determination to do more on building overall capacity. As my hon. Friend the Member for Stafford (Theo Clarke) and others point out, Gavi, the Vaccine Alliance is really important, and we continue to be a leading supporter. Our commitment of £1.65 billion over five years will help to vaccinate 300 million more children against preventable disease and improve health system resilience against future pandemics.

[Navendu Mishra]

Will the Minister give way?

[Mr Philip Hollobone (in the Chair)]

Order. We do not have time for an intervention, I am afraid. Wendy Chamberlain has to sum up. The Minister will draw her remarks to a close.